We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.16 | 0.58% | 27.86 | 27.905 | 27.52 | 27.86 | 60,567,753 | 00:59:06 |
From May 2022 to May 2024
By Colin Kellaher
Pfizer Inc. on Thursday said the U.S. Food and Drug Administration granted breakthrough-therapy designation to its investigational cancer immunotherapy elranatamab for the treatment of relapsed or refractory multiple myeloma.
The FDA's breakthrough-therapy designation aims to expedite the development and review of a drug for serious conditions when preliminary clinical evidence shows the drug may show substantial improvement over available therapies.
The New York drugmaker said people with multiple myeloma whose disease has relapsed or is refractory to existing treatments currently have few avenues for staving off the currently incurable blood cancer.
Pfizer previously received FDA orphan-drug and fast-track designation for elranatamab.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 03, 2022 09:40 ET (13:40 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
